|
CELG's Net Cash Flow Growth by Quarter and Year
Celgene's Net Cash Flow results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Net Cash Flow Growth Y/Y▼
|
Net Cash Flow Growth Y/Y▼
|
CELG Net Cash Flow (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
IV Quarter |
December |
-
|
1,754.00
|
1,502.00
|
647.30
|
III Quarter |
September |
2,390.00
|
977.00
|
-1,149.00
|
458.90
|
II Quarter |
June |
1,781.00
|
-1,316.00
|
1,387.00
|
618.20
|
I Quarter |
March |
1,199.00
|
-4,194.00
|
-897.00
|
-434.80
|
FY |
|
5,370.00
|
-2,779.00
|
843.00
|
1,289.60
|
CELG Net Cash Flow third quarter 2019 Y/Y Growth Comment |
Celgene Corp achieved in the third quarter 2019, above Company average Net Cash Flow surge of 144.63% year on year, to $ 2,390.00 millions.
Among companies who have reported third quarter 2019 results in the Major Pharmaceutical Preparations industry only one Company has achieved higher year on year Net Cash Flow results in the third quarter 2019. While Celgene Corp' s Net Cash Flow doubling of 144.63% ranks overall at the positon no. 79 in the third quarter 2019.
|
CELG Net Cash Flow ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
16.78 % |
132.04 % |
- |
III Quarter |
September |
144.63 % |
- |
- |
-69.11 % |
II Quarter |
June |
- |
- |
124.36 % |
279.03 % |
I Quarter |
March |
- |
- |
- |
- |
FY |
|
- |
- |
-34.63 % |
69.97 % |
CELG Net Cash Flow (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
79.53 % |
- |
41.05 % |
III Quarter |
September |
34.19 % |
- |
- |
-25.77 % |
II Quarter |
June |
48.54 % |
- |
- |
- |
I Quarter |
March |
-31.64 % |
- |
- |
- |
FY (Year on Year) |
|
- |
- |
-34.63 % |
69.97 % |
Net Cash Flow Y/Y Growth Statistics |
High |
Average |
Low |
749.48 % |
63.63 % |
-95.38 % |
(Dec. 31, 2006) |
|
(Sep. 30, 2007) |
|
Net Cash Flow Y/Y Growth Statistics |
High |
Average |
Low |
749.48 % |
63.63 % |
-95.38 % |
(Dec. 31, 2006) |
|
(Sep. 30, 2007) |
|
Net Cash Flow by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Celgene's Q/Q Net Cash Flow Growth
Net Cash Flow Q/Q Growth Statistics |
High |
Average |
Low |
60229.21 % |
2383.35 % |
-100 % |
(Sep. 30, 2012) |
|
|
CELG's III. Quarter Q/Q Net Cash Flow Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Net Cash Flow jump of 34.19% quarter on quarter, to $ 2,390.00 millions.
III. Quarter 2019 Net Cash Flow Q/Q growth were contradictory, albeit below the ordinary, yet it shows real recovery compare to the % in the III. Quarter 2018.
Within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Net Cash Flow quarter on quarter growth. While Celgene's Net Cash Flow growth quarter on quarter, overall rank is 180. |
|
|
Net Cash Flow Q/Q Growth Statistics |
High |
Average |
Low |
60229.21 % |
2383.35 % |
-100 % |
(Sep. 30, 2012) |
|
|
CELG's III. Quarter Q/Q Net Cash Flow Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Net Cash Flow jump of 34.19% quarter on quarter, to $ 2,390.00 millions.
III. Quarter 2019 Celgene's results were contradictory, albeit below the ordinary, yet it demonstrates a quite recovery compare to the % in the III. Quarter 2018 Isabel Nelson, Healthcare sector expert based in Toronto wrote.
Within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Net Cash Flow quarter on quarter growth. While Celgene's Net Cash Flow growth quarter on quarter, overall rank is 180. |
|
Celgene's 12 Months Net Cash Flow Growth Year on Year
Net Cash Flow TTM Growth |
12 Months Ending (Sep 30 2019) |
12 Months Ending (Jun 30 2019) |
12 Months Ending (Mar 31 2019) |
12 Months Ending (Dec 31 2018) |
12 Months Ending (Sep 30 2018) |
Cumulative Net Cash Flow 12 Months Ending |
$ 7,124.00 |
$ 5,711.00 |
$ 2,614.00 |
$ -2,779.00 |
$ -3,031.00 |
Y / Y Net Cash Flow Growth (TTM) |
- |
- |
- |
- |
- |
Year on Year Net Cash Flow Growth Overall
Ranking |
# |
# |
# |
# |
# |
Seqeuential Net Cash Flow Change (TTM) |
24.74 % |
118.48 % |
- |
- |
- |
Seq. Net Cash Flow Growth (TTM) Overall
Ranking |
# 208 |
# 146 |
# 0 |
# 0 |
# 0 |
Cumulative Net Cash Flow growth
Comment |
Celgene saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 144.63% year on year, to $ 7,124 millions if the fiscal year would have ended in Sep 30 2019. Celgene's trailing twelve months Net Cash Flow growth was higher than company's average 0% and higher than % growth in Jun 30 2019. And, Celgene realized the fastest Net Cash Flow growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Jun 30 2019 rise was beneth at 24.74 % from $5711 millions achieved in the period from Jun 30 2019 to Sep 30 2018 Isabel Nelson continued. Still this was validation of strength, as the usual Q/Q TTM Net Cash Flow growth stands at -87.52%. In the Sep 30 2019 period, Celgene had cumulative twelve months Net Cash Flow of $ 7,124 millions compare to net cash outflow of $ -3,031 millions a year ago. Even more so, not just that CELG has restored the profitability, the company by this time is gaining momentum with better then average Net Cash Flow gain, from the period from Jun 30 2019 to Sep 30 2018 of 24.74 % from $5711 millions.
Celgene Corp achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. . |
Net Cash Flow TTM Q/Q Growth Statistics |
High |
Average |
Low |
963.5 % |
-87.52 % |
-1057.1 % |
|
|
|
|
|
Net Cash Flow TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Net Cash Flow TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 8 |
Sector |
# 25 |
S&P 500 |
# 208 |
|
Cumulative Net Cash Flow growth
Comment |
Celgene saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 144.63% year on year, to $ 7,124 millions if the fiscal year would have ended in Sep 30 2019. Celgene's trailing twelve months Net Cash Flow growth was higher than company's average 0% and higher than % growth in Jun 30 2019. And, Celgene realized the fastest Net Cash Flow growth, in Major Pharmaceutical Preparations industry. But sequential increase was slower at 24.74 % from $5711 millions recorded in twelve months ending a quarter before. Still this was evidence of strength, while the average Q/Q TTM Net Cash Flow gain is at -87.52%. The momentum is even higher from the previous reporting period clinched at 24.74 % rise from $5711 millions in the period from Jun 30 2019 to Sep 30 2018. In the Sep 30 2019 period, Celgene had cumulative twelve months Net Cash Flow of $ 7,124 millions compare to net cash outflow of $ -3,031 millions a year ago. Besides Major Pharmaceutical Preparations company has returned to bottom-line, the company is, as of now gaining momentum and showing higher than usual Net Cash Flow rise, from the twelve months ending in the quarter Jun 30 2019 of 24.74 % from $5711 millions.
Celgene Corp achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. . |
Net Cash Flow TTM Q/Q Growth Statistics |
High |
Average |
Low |
963.5 % |
-87.52 % |
-1057.1 % |
|
|
|
Net Cash Flow TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Net Cash Flow TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 8 |
Sector |
# 25 |
S&P 500 |
# 208 |
|